Curada

Curada is building the first FDA-cleared digital therapeutic to reverse endorphin-based compulsions — starting with alcohol misuse. The protocol behind it — once buried in a Finnish state lab — now holds 125 studies, 93% success, and full medical licensing in the UK/EU. Still, it’s absent from U.S. standard of care — despite an 800% surge in alcohol-related deaths and $260B in annual harm. We’re changing that — fast. Curada integrates medical eligibility, digital prescribing, AI protocol guidance, and automated adherence into a seamless, scalable platform. A 30K-strong grassroots community of adopters, clinicians, and advocates is shifting the paradigm — from abstinence to Nobel-recognized extinction. Backed by Techstars London, we’re pursuing FDA Breakthrough Device Designation and scaling DTC in the UK — unlocking a 770M-person global market failed by pre-science treatment. This is behavior neuroengineering — at scale. 📍 HQ: NYC 💥 $1.1M bridge-to-seed round open (Q3 2025)